Antiplatelet Therapy
1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 2002;324: 71–86.
2. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 1996;348:1329–39.
3. Wiviott SD, Trenk D, Frelinger AL, et al., Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial,
Circulation, 2007;116:2923–32.
4. Montalescot G, Sideris G, Meuleman C, et al., A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial, J Am Coll Cardiol,
2006;48:931–8.
5. von Beckerath N, Taubert D, Pogatsa-Murray G, et al., Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial, Circulation, 2005;112:2946–50.
6. Mehta SR, for the CURRENT investigators, A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial, ESC Congress 2009, ESC Congress 2009, 2009; presentation 177. Available at: spo.escardio.org/eslides/ view.aspx?eevtid=33&id=177
7. Wiviott SD, Braunwald E, McCabe CH, et al., Prasugrel versus clopidogrel in patients with acute coronary
syndromes, N Engl J Med, 2007;357:2001–15.
8. Bassand JP, Hamm CW, Ardissino D, et al., Guidelines
for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes, Eur Heart J, 2007;28:1598–1660.
9. Wallentin L, Becker RC, Budaj A, et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes,
N Engl J Med, 2009;361:1045–57.
10. Airoldi F, Colombo A, Morici N, et al., Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment,
Circulation, 2007;116:745–54.
11. Kimura T, Morimoto T, Nakagawa Y, et al., Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation, Circulation, 2009;119:987–95.
12. Wiviott SD, Braunwald E, McCabe CH, et al., Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial, Lancet, 2008;371: 1353–63.
52
EUROPEAN CARDIOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92